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Objective. There is limited data on abdominal obesity and the influence of genetics on weight change after antiretroviral therapy 
(ART) initiation. We assessed body mass index (BMI) and waist hip ration (WHR) change over time in the Swiss HIV Cohort study 
(SHCS).
Methods. Mixed-effects models characterizing BMI and WHR change over time in 1090 SHCS participants initiating ART be-
tween 2005 and 2015 were developed and used to quantify the influence of demographics, clinical factors, and genetic background.
Results. Individuals with CD4 nadir <100 cells/µL gained 6.4 times more BMI than individuals with ≥200, and 2.8 times more 
WHR than individuals with ≥100 (P < .001) during the first 1.5 and 2.5 years after ART initiation, respectively. The risk of being over-
weight or obese after 1.5 years increased with CD4 nadir <100 cells/µL compared to 100–199 (odds ratio [OR], 2.07; 95% confidence 
interval [CI], 1.63–2.74) and ≥200 (OR, 1.69; 95% CI, 1.26–2.32), persisting after 10 years of ART. The risk of abdominal obesity after 
2.5 years increased with CD4 nadir <100 compared to ≥100 (OR, 1.35; 95% CI, 1.17–1.54 [in men]; OR, 1.36; 95% CI, 1.18–1.57 [in 
women]), persisting after 10 years of ART. No significant differences were found across antiretroviral drug classes or genetic scores.
Conclusions. The risk of general and abdominal obesity increased with CD4 nadir <100 cells/µL. Based on our results, including 
the genetic background would not improve obesity predictions in HIV-infected individuals.
Key words: abdominal obesity; antiretroviral therapy; body mass index; genetics; nadir CD4 cell count; obesity; waist-hip ratio.
INTRODUCTION
Antiretroviral therapy (ART) has dramatically decreased the 
incidence of AIDS and HIV-related mortality. However, with 
the increase in life expectancy for people living with HIV, 
aging-related complications (such as cardiovascular (CV) dis-
ease, liver disease, renal function decline, and certain cancers) 
have emerged as important causes of morbidity and mortality 
in HIV [1–3]. Cardiovascular disease remains the second most 
common cause of death in the HIV-infected population after 
malignancies, which has placed care and treatment of CV risk 
factors, such as obesity, among the primary concerns of current 
HIV management [4–7].
General [8–10] and abdominal obesity have been steadily 
increasing in HIV-infected populations over the last decade, 
and weight gain frequently follows ART initiation [11–13]. Early 
weight gain during ART has been associated with a higher CV 
risk [13–15]. Certain ART combinations have been associated 
with a higher CV risk, perturbations in glucose and lipid metab-
olism, and metabolic syndrome [16–19]. There is emerging evi-
dence of an association between weight gain and current widely 
used antiretroviral drugs, such as integrase strand transfer in-
hibitors (INSTI) and tenofovir alafenamide (TAF) [20–24]. 
Despite the fact that a genetic basis of general and abdominal 
obesity is well established, limited information is available in 
HIV-infected populations [25, 26]. Our hypothesis is that the 
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genetic determinants of general and abdominal obesity identi-
fied in the HIV-negative general population would have a sim-
ilar impact on the HIV-infected population.
In this study, we selected body mass index (BMI) and waist-
hip ratio (WHR) as anthropometric indicators of general and 
abdominal obesity, respectively. First, we describe obesity trends 
and concurrent demographic changes in the Swiss HIV Cohort 
Study (SHCS). Then, we use mixed-effects statistical modelling 
to describe BMI and WHR changes over time in SHCS parti-
cipants initiating ART and quantify the relative contribution 
of clinical, HIV-related, and genetic factors. The assessment of 
these anthropometric indicators over time and a better under-
standing of its relationship with traditional and HIV-related 
risk factors could help identify individuals that could benefit 
from early interventions to reduce CV risk.
METHODS
Study Population and Longitudinal Data
Participants were enrolled in the SHCS (www.shcs.ch). For the 
descriptive longitudinal analysis, we included all SHCS partici-
pants with ≥1 available measures of BMI (1990–2017) and WHR 
(2000–2017). For the mixed-effects longitudinal analyses of 
BMI and WHR gain, we included a subset of SHCS participants 
that initiated ART between January 1, 2005, and December 31, 
2015, with ≥1 BMI and WHR measurement close to ART ini-
tiation date (defined as baseline, maximum 18 months before 
ART initiation) and at least another measurement after January 
1, 2011, to ensure the inclusion of contemporary ART regimens. 
Demographic, clinical, and pharmacological characteristics 
were extracted from the SHCS database. Local ethics commit-
tees approved the study and all participants provided written 
informed consent for genetic testing.
Body Composition Measures
Body mass index was determined by dividing body weight 
(kg) by height squared (m2). Waist-hip ratio was determined 
by dividing waist circumference (cm) by hip circumference 
(cm). Individuals were classified according to the World Health 
Organization (WHO) cut-offs for overweight (BMI ≥  25  kg/
m2) and abdominal obesity (WHR > 0.9 for men and >0.85 for 
women) [27, 28].
Descriptive Longitudinal Analysis
At each SHCS semiannual visit, participants undergo a phys-
ical examination and provide biological specimens and stand-
ardized information on demographics, HIV characteristics, and 
current ART. Whole body dual-energy X-ray absorptiometry or 
single slice abdominal computer tomography scans are not rou-
tinely performed in the SHCS. Lipodystrophy is assessed clin-
ically at each SHCS semiannual visit based on physician and 
patient agreement on significant fat loss and/or fat accumula-
tion on physical examination, in any of the following regions: 
face, arms, legs, buttocks, abdomen, breasts, and neck. The me-
dian BMI and WHR and the percentage of SHCS participants 
in each obesity category were used to summarize the distribu-
tion of BMI (1990–2017) and WHR (2000–2017) following the 
WHO classification [27, 28].
BMI and WHR Change Models
Piecewise linear mixed-effects models were developed to de-
scribe BMI and WHR change over time using natural log-
transformed BMI and WHR data (NONMEM v7.4.0, ICON 
development Solutions, Ellicott City, MD). This approach al-
lows the estimation of average population parameters, between 
and within-subject variability, and influence of demographic, 
clinical, pharmacological, and genetic factors.
The parameters estimated by the models were BMI and WHR 
baseline, corresponding to the BMI or WHR value at ART in-
itiation, and BMI and WHR change per year at different time 
intervals after ART initiation. Random effects were integrated 
to describe between and within subject variability of all param-
eters. Correlations between random effects were included when 
identifiable and favorable for the model fit.
Model selection was based on diagnostic plots, parameters 
estimates precision, and log-likelihood ratio test (reduction of 
the objective function value [OFV] provided by NONMEM). 
Significant thresholds were fixed at P < .05 and P < .005 for the 
stepwise forward inclusion and backwards deletion covariate 
selection, respectively (ΔOFV between any 2 nested models ap-
proximates a χ2 distribution). Model development, documenta-
tion, and evaluation was aided by Perl-speaks-NONMEM (PsN; 
https://uupharmacometrics.github.io/PsN/) toolkit (version 
4.2) and Pirana (Certara, Princeton, NJ, USA) v2.9.2. R v3.3.1 
(Rstudio v.1.1.423; Integrated Development for R. RStudio, Inc., 
Boston, MA, USA) was used for data management, statistical 
analysis, and graphical output (see Supplementary Data).
Demographic, Clinical, and Pharmacological Factors
We tested the influence of age, gender, self-reported ethnicity, 
nadir CD4 cell count categories (<100, 100–199 and ≥200 cells/
μL), smoking status (current, never, past), intravenous drug use 
(IDU) as assumed transmission mode, diabetes mellitus, and 
hepatitis C coinfection on BMI and WHR baseline and change 
per year. Given the correlation between BMI and WHR, the latter 
was tested in the BMI model and vice versa. Missing data in con-
tinuous covariates were imputed to the population median value, 
whereas missing data in categorical covariates were first coded as 
an additional category and then regrouped according to param-
eter estimates. The impact of antiretroviral drug classes on BMI 
and WHR gain was studied in patients that maintained the same 
ART regimen over the time intervals defined by the models.
Genetic Factors
Samples of DNA obtained from peripheral blood mononuclear 
cells were genotyped with the Infinium CoreExome-24 BeadChip 
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(Illumina, San Diego, CA) or obtained in the context of previous 
Genome-wide Association Studies (GWAS) in the SHCS on var-
ious platforms, including the HumanCore-12, HumanHap550, 
Human610, Human1M, and HumanOmniExpress-24 BeadChips 
(Illumina, San Diego, CA). Each cohort was filtered and imputed 
separately, with variants first flipped to the correct strand with 
BCFTOOLS (http://samtools.github.io/bcftools/bcftools.html) 
(v1.8) according to the human GRCh37 reference genome and fil-
tered based on a <20% deviation from the 1000 genomes phase 
3 EUR reference panel. Genotypes were phased with EAGLE2 
and missing genotypes were imputed with PBWT; both processes 
used the 1000 Genomes Project Phase 3 reference panel on the 
Sanger Imputation Service [29–31]. Imputed variants were filtered 
by minor allele frequency (>1%), missingness (<10%), deviation 
from Hardy-Weinberg equilibrium (P < 1e-6), and an imputation 
quality score (INFO>0.8). The filtered genotypes then were com-
bined using PLINK (v1.90b5) prior to analyses [31].
For the present study, we retrieved genetic information for 
90 and 46 statistically independent (r2 < 0.2) single nucleotide 
polymorphisms (SNPs) significantly associated with higher 
BMI and WHR, respectively, according to recent GWAS meta-
analyses conducted in the general population (Supplementary 
Tables 4 and 5) [32, 33]. Based on these SNPs, we calculated 
both an additive genetic risk score (GRS) by summing the 
number of risk alleles (0, 1, 2) carried by the individual for each 
SNP, and a weighted genetic risk score by summing the product 
of the number of risk alleles corrected by the effect size of the 
SNP as reported in the reference papers [32, 33]. Study partici-
pants were divided in 4 genetic risk score quartiles (most favor-
able genetic background = 1st quartile; most unfavorable = 4th 
quartile). The influence of genetic risk scores was tested in the 
subpopulation of Caucasian participants as a continuous and as 
a categorical covariate, using genetic score quartiles.
Model-Based Predictions of BMI and WHR Over Time
Final models including relevant variables influencing BMI 
and WHR gain over time were validated using standard tech-
niques (ie, nonparametric bootstrap, goodness of fit plots, and 
prediction-corrected visual predictive check). Model param-
eter estimates (coefficients and covariates effects) obtained by 
bootstrapping final models (resampling n = 2000) were used to 
predict BMI and WHR values over a 10-year period for 10 000 
individuals after ART initiation and to estimate the risk of 
preobesity and abdominal obesity at different time points.
RESULTS
Descriptive Longitudinal BMI and WHR Trends (1990–2017)
Obesity categories and median BMI and WHR trends in the en-
tire SHCS population stratified by calendar year are shown in 
Figure 1A and 1B. From 1990 to 2017, median BMI and the 
percentage of overweight and obese participants increased. 
From 2000 to 2017, median WHR and the percentage of male 
and female participants with abdominal obesity increased. In 
2017, median BMI was 24.4 kg/m2 (interquartile range [IQR], 
22.0–27.4), median WHR was 92.9 (IQR, 87.6–98.0), and 52% 
of the population were normal weight, 4% were underweight, 
32% were overweight, 12% were obese, and 71% had abdominal 
obesity. From 1990 to 2017, the percentage of Caucasian par-
ticipants, IDUs, and participants with AIDS-defining illnesses 
decreased. The percentage of women, participants on ART, the 
median CD4 cell count at ART initiation, and the median age of 
participants increased.
BMI Change Model
One thousand and ninety participants fulfilled the criteria for 
longitudinal BMI analysis. Median follow-up was 8.2  years 
(range, 2.6 to 12 years) (Table 1 and Supplementary Table 1). Gain 
over time for BMI was best described using time intervals, each 
defining different rates of BMI change per year (P < .001, com-
pared to models with 1–2 intervals). The first interval covered 
the period from ART initiation to 1.5 years of ART and showed 
a median yearly BMI gain of 0.25 (95% confidence interval [CI], 
0.18–0.33) kg/m2. The second interval covered the period from 
1.5 to 3 years of ART and showed a yearly median BMI gain of 
0.17 (95% CI, 0.11–0.23) kg/m2. The third interval covered the 
period from 3 years of ART until last follow-up and showed a me-
dian yearly BMI gain of 0.09 (95% CI, 0.06–0.11) kg/m2 (Table 2).
Age, WHR, never or past smoking, African ethnicity, and 
diabetes mellitus were associated with higher baseline BMI. 
Asian ethnicity and nadir CD4 cell count <200 cells/μL were 
associated with lower baseline BMI (Table 2). Nadir CD4 cell 
count was the only covariate showing a significant effect on 
yearly BMI change after ART initiation. Between initiation and 
1.5 years of ART, individuals with nadir CD4 cell count <100 
cells/μL and with 100–199 cells/μL gained 6.4 times (95% CI, 
4.2–8.5; P < .001) and 2.1 times (95% CI, 1.8–2.9; P < .001) more 
BMI per year, respectively, than individuals with nadir CD4 cell 
count ≥200 cells/μL.
No antiretroviral drug class showed a significant influence on 
yearly BMI change in the 2 time periods tested (0–1.5 years n = 908 
and 1.5–3 years n = 705; P > .05; Supplementary Tables 1 and 6). 
Further analyses on individual drugs thus were not undertaken. 
Regarding the genetic risk tested in 863 Caucasian participants, the 
strongest association in univariate analyses was found between the 
additive genetic risk score (aGRS) and BMI change after 3 years of 
ART. In univariable analysis, yearly BMI gain was 6.7% higher (95% 
CI, 1–13%; P < .05) with each additional unit of aGRS compared 
to the median population value (median aGRS  =  86). A  weaker 
association was observed with aGRS quartiles and with weighted 
genetic risk scores (wGRS) in continuous or quartile forms. The im-
pact of the genetic risk was not retained after adjustment for mul-
tiple covariates. No effect of genetic risk was found on other model 
parameters (Supplementary Table 6). Model development steps and 
validation assessments can be found in the Supplementary Data.
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Figure 1. Descriptive Longitudinal Trends for All Swiss HIV Cohort Study Participants. A, descriptive longitudinal BMI trends for all Swiss HIV Cohort Study participants 
(SHCS), 1990–2017. Obesity classification according to the World Health Organizaiton: underweight (BMI < 18.5 kg/m2), normal weight (BMI = 18.5–24.9 kg/m2), overweight 
(BMI = 25–29.9 kg/m2), and obese (BMI ≥ 30 kg/m2). Lipodystrophy reflects significant fat loss and/or fat accumulation in face, arms, legs, buttocks, abdomen, breasts, or 
neck, which was clinically assessed by physician with patient agreement and confirmed over a ≥6-month interval. B, Descriptive longitudinal WHR trends for all SHCS par-
ticipants, 2000–2017. Longitudinal trends of population abdominal obesity categories and median WHR trajectory, entire Swiss HIV Cohort Study population, 2000–2017. 
The proportion of SHCS participants with normal WHR (shaded areas) steadily decreased, while the proportion with abdominal obesity (weight areas) increased, among both 
men and women. Abdominal obesity classification according to the World Health Organization: WHR >0.9 for men and >0.85 for women. Confidence intervals are omitted 
for visual clarity. AIDS indicates acquired immune deficiency syndrome; ART, antiretroviral therapy; BMI, body mass index; IDU, injection drug user; WHR, waist-hip ratio.
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WHR Change Model
One thousand participants fulfilled the criteria for longitudinal 
WHR analysis. Median follow-up was 8.2  years (range 4 to 
12 years) (Table 1 and Supplementary Table 1). In line with BMI, 
WHR gain over time was best described using 3 time intervals, 
each with different rates of WHR change per year (P  <  .001, 
compared to models with 1–2 intervals). The first interval cov-
ered the period from ART initiation to 2.5 years of ART and 
showed a median WHR gain of 0.0039 (95% CI, 0.002–0.005) 
units per year. The second interval covered from 2.5 to 4 years 
of ART and showed a median WHR gain of 0.0038 (95% CI, 
0.002–0.006) units per year. The third interval covered from 
4 years of ART until last follow-up and showed a median WHR 
gain of 0.0029 (95% CI, 0.002–0.004) units per year (Table 2).
Male gender, age, and BMI at baseline were associated with 
higher baseline WHR. Nadir CD4 cell count was the covariate 
showing the largest effect on yearly WHR change after ART in-
itiation. Between initiation and 2.5  years of ART, individuals 
with nadir CD4 cell count <100 cells/μL gained 2.8 times (95% 
CI, 1.6  –3.9; P  <  .001) more WHR per year than individuals 
with nadir CD4 cell count ≥100 cells/μL. Between 4  years of 
ART until end of follow up, African and Hispanic individuals 
gained 2 times (95% CI, 1.1–2.9; P < .005) more WHR per year 
than other ethnicities.
During the first 2.5 years of ART, individuals with protease 
inhibitor-based regimens showed less WHR gain per year than 
other regimens (-58% 95% CI, -109–-8%; P < .05) in univariable 
analysis, but this effect was not significant in multivariate ana-
lyses. No antiretroviral drug class showed a significant influence 
on WHR change at other time intervals. Further analyses of in-
dividual drugs thus were not undertaken. No statistically signif-
icant association was found between WHR model parameters 
and genetic risk scores tested in 575 Caucasian participants, 
neither in continuous (P > .24) nor categorical form (P > .13) 
(Supplementary Table 7). Model development steps and valida-
tion assessments can be found in the Supplementary Data.
BMI Predictions Over Time
Predictions of BMI at baseline and 1.5, 3, and 10 years after ART 
initiation are shown in Table 3 and Figure 2. After 1.5 years of ART, 
individuals with a nadir CD4 cell count <100 cells/μL had a higher 
risk of being overweight or obese than individuals with a nadir CD4 
Table 1. Characteristics at Time of Antiretroviral Therapy Initiation of Subpopulation Included the Body Mass Index and Waist-Hip Ratio Models
Characteristics BMI Change Model (n = 1090) WHR Change Model (n = 1000)
Sex (male), n (%) 868 (80) 798 (80)
Age (years), median (range) 40 (19–76) 40 (19–75)
BMI (kg/m2), median (range) 23.3 (14.9–63.4) 23.2 (14.9–63.4)
Underweight, n (%) 56 (5) 50 (5) 
Normal weight, n (%) 687 (63) 637 (64)
Overweight, n (%) 282 (26) 255 (25)
Obesity, n (%)a 65 (6) 58 (6)
WHR, median (range) 0.89 (0.56–1.13) 0.89 (0.56–1.45)
Missing data, n (%) 90 (8)  
Men >0.9, n (%) 458 (58) 432 (54)
Women >0.85, n (%) 90 (43) 87 (43)
Ethnicity   
Caucasian, n (%) 934 (86) 857 (86) 
African 88 (8) 82 (8)
Hispanic, n (%) 36 (3) 31 (3)
Asian, n (%) 32 (3) 30 (3)
Nadir CD4 cell count   
≤99, n (%) 109 (10) 106 (10)
100–199, n (%) 211 (19) 207 (21)
≥200, n (%) 770 (71) 687 (69)
History of AIDS-defining event, n (%) 114 (10) 109 (11)
Injection drug use, n (%) 80 (7) 71 (7)
Hepatitis C coinfection, n (%) 153 (14) 143 (14)
Diabetes mellitus, n (%) 38 (4) 34 (3)
Smoking status   
Current, n (%) 592 (54) 543 (54)
Never, n (%) 447 (41) 416 (42)
Past, n (%) 51 (5) 41 (4)
Abbreviations: BMI, body mass index; WHR, wasit-hip ratio. 
aObesity classification according to the World Health Organization: underweight (BMI < 18.5 kg/m2), normal weight (BMI = 18.5–24.9 kg/m2), overweight (BMI = 25–29.9 kg/m2), and obe-
sity (BMI ≥ 30 kg/m2).
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cell count of 100–199 cells/μL (OR = 2.07; 95% CI, 1.63–2.74) or 
of ≥200 cells/μL (OR = 1.69; 95% CI, 1.26–2.32). After 10 years of 
ART, the risk of being overweight or obese remained significantly 
higher in these individuals compared to individuals with a nadir 
CD4 cell count of 100–199 cells/μL (OR = 1.85; 95% CI, 1.52–2.32) 
or of ≥200 cells/μL (OR = 1.55; 95% CI, 1.23–2.02). The risk of being 
overweight or obese was not significantly different between individ-
uals with a nadir CD4 cell count of 100–199 cells/μL and ≥200 cells/
μL after 1.5 years (OR = 0.81; 95% CI, 0.65–1.00) or 10 years of ART 
(OR = 0.84; 95% CI, 0.7–1.00).
Table 3. Model-Based Body Mass Index Change Predictionsa
BMI Predictions
Time After ART Initiation (Years)
1.5 3 10
BMI change from ART initiation (kg/m2)
CD4Nadir ≥ 200 cells/µL +0.3 (-0.2, +0.7) +0.6 (-0.4, +1.4) +1.3 (-1.3, +3.1)
CD4Nadir 100–199 cells/µL +0.8 (+0.2, +1.1) +1.0 (-0.05, +1.8) +2.2 (-0.9, +3.6)
CD4Nadir < 100 cells/µL +2.4 (+1.8, +2.8) +2.7 (+1.5, +3.5) +3.3 (+0.7, +5.3)
Body weight change from ART initiation (kg, in a typical individual of 1.7 m height)
CD4Nadir ≥ 200 cells/µL +1.0 (-0.7, +2.0) +1.8 (-1.2, +3.9) +3.7 (-3.7, +9.1)
CD4Nadir 100–199 cells/µL +2.2 (+0.4, +3.3) +2.9 (-0.1, +5.2) +6.4 (-2.7, +10.4)
CD4Nadir < 100 cells/µL +6.9 (+5.1, +8.1) +7.7 (+4.5, +10.0) +9.6 (+2.0, +15.2)
Abbreviations: ART, antiretroviral therapy; BMI, body mass index. 
aAll results are predictive median (95% prediction interval).
Table 2. Final Body Mass Index and Waist-Hip Ratio Model Estimates
BMI Model Estimate (RSE %) Between-Subject Variability (CV%)
Baseline BMI (kg/m2)a 23.3 (1) 14 (6)
BMI change per year (kg/m2/y)   
from 0 to 1.5y after ART start 0.25 (14) 344 (12)
from 1.5 to 3y after ART start 0.17 (18) 465 (11)
>3y after ART start 0.09 (14) 388 (10)
Covariate effects on baseline BMI (%)b   
70 years old vs 40 years old +6 (24)  
WHR 1 vs 0.80 +3 (16)  
Past or never smoking +3 (27)  
Diabetes mellitus +17 (25)  
African ethnicity +7 (30)  
Asian ethnicity -9 (25)  
CD4Nadir < 200 cells/µL vs CD4Nadir ≥ 200 cells/µL -4 (26)  
Covariate effects on BMI change per year from 0 to 1.5 years (%)b   
CD4Nadir < 100 cells/µL vs CD4Nadir ≥ 200 cells/µL +540 (21)  
CD4Nadir100-199 cells/µL vs CD4Nadir ≥ 200 cells/µL +110 (42)  
WHR Model Estimate (RSE %) Between-Subject Variability (CV%)
Baseline WHR a 0.84 (0.4) 5.5 (5)
WHR change per year (units/y)   
From 0 to 2.5y after ART start 0.0039 (19) 396 (6)
From 2.5 to 4y after ART start 0.0038 (28) 629 (9)
>4y after ART start 0.0029 (14) 269 (7)
Covariate effects on baseline WHR (%)b   
70 years old vs 40 years old +7 (8)  
BMI 30 vs 25 +3 (7)  
Male gender +8 (6)  
Covariate effects on WHR change per year from 0 to 2.5 years (%)b   
CD4Nadir < 100 cells/µL compared to CD4Nadir ≥ 100 cells/µL +180 (33)  
Covariate effects on WHR change per year >4 years (%)b   
African or Hispanic ethnicity +100 (46)  
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; RSE, relative standard error defined as standard error/estimate; WHR, waist-hip ratio. 
aBaselines of BMI and WHR correspond to the estimated BMI or WHR value at ART initiation. 
bRelative effects of covariates are expressed as a percentage compared to the reference.
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WHR Predictions Over Time
Predictions of WHR at baseline and 2.5, 4, and 10 years after 
ART initiation are shown in Figure 2. After 2.5 years of ART, 
individuals with a nadir CD4 cell count <100 cells/μL had a 
higher risk of abdominal obesity than individuals with a nadir 
CD4 cell count ≥100 cells/μL (OR  =  1.35; 95% CI, 1.17–1.54 
[for men]; OR = 1.36; 95% CI, 1.18–1.57 [for women]). After 
10 years of ART, the risk of abdominal obesity remained sig-
nificantly higher in these individuals compared to individuals 
with a nadir CD4 cell count of ≥100 cells/μ group (OR = 1.58; 
95% CI, 1.28–2.02 [for men]; OR = 1.59; 95% CI, 1.29–2.03 [for 
women]).
DISCUSSION
Previously, CD4 nadir has been recorded as predictor of weight 
gain after ART start by us [8] and others [11, 13, 34, 35]. In line 
with recent studies, our results show that a low nadir CD4 count 
is a significant risk factor for developing general and abdom-
inal obesity [36, 37]. The approximately 2-fold increased risk 
of overweight and general obesity and almost 60% increased 
risk of abdominal obesity associated with CD4 nadir<100 cells/
μL was first noted at 1.5 years of ART but persisted at 10 years 
of ART.
The previously described notion that low CD4 nadir is as-
sociated with recovery of weight lost during chronic untreated 
HIV infection should be extended to include low CD4 nadir 
as an important risk factor for long term general and abdom-
inal obesity risk, likely in the setting of immunometabolic dis-
turbances [6, 38–40]. Particularly in those with low CD4 nadir, 
body weight and abdominal fat accumulation after ART initia-
tion may go beyond normal body weight and fat recovery [14]. 
Our data provide an additional justification for current guide-
lines recommending early ART initiation beyond well-recorded 
benefits in terms of prevention of immunodeficiency, oppor-
tunistic complications, and non-AIDS events [41].
We also reveal differences between early and long-term 
BMI and WHR changes after ART initiation and factors of 
potential clinical relevance. Consistent with previous data [8, 
11, 13], the BMI and WHR models revealed an average con-
tinuous gain over the study period, more important during 
the early years after ART initiation. Despite limited average 
BMI and WHR increases per year (0.3% to 1.1%, respectively), 
both our models predicted a substantial increase in general 
and abdominal obesity after 10 years of ART [10, 42, 43]. To 
our knowledge, this is the most comprehensive longitudinal 
assessment of BMI and WHR in a HIV-positive population, 
showing a stabilization after about 3 and 4  years, respec-
tively, that resembles BMI and WHR changes over time in the 
general population [11, 44].
Finally, we extend our previous descriptive assessment [8] of 
the demographic transformation (ie, aging population, fewer 
IDU, earlier ART start, more complete ART coverage of popu-
lation) that accompanied the increasing prevalence of obesity in 
the SHCS population 1990–2012 to the time period 2013–2017. 
Increasing obesity rates in other HIV cohorts have been de-
scribed previously [8, 39]. Slightly over 50% of the SHCS pop-
ulation remains normal weight in 2017, similarly to the general 
population in Switzerland with 42% of overweight or obese 
[45]. Interestingly, increasing prevalence of abdominal obesity 
in the SHCS in recent years seems to coincide with a decrease 
in lipodystrophy prevalence during the same time period, sug-
gesting that our clinical lipodystrophy assessments (physician 
and patient agreement on abnormal fat loss/fat accumulation, 
confirmed over a ≥6-month interval) are valid and do not 
simply capture increasing general and abdominal obesity trends 
in the SHCS over time.
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Traditional risk factors like age, gender, smoking habit, di-
abetes mellitus, and ethnicity showed a considerable impact 
on general and abdominal obesity prevalence in this popula-
tion of HIV patients [46]. These results emphasize the evolu-
tion of SHCS participants towards an older population at higher 
cardiovascular risk.
In line with previous studies, we did not find any impact nor 
differences among antiretroviral drug classes on BMI and WHR 
changes, suggesting the necessity to monitor changes in body 
weight and abdominal fat with all currently recommended ART 
regimens [12, 47, 48]. The large between-subject variability in 
BMI and WHR changes over time and the reduced number of 
participants with the same ART regimen over the first 3 and 
4 years, respectively, might have masked this effect. In contrast 
with some past ART regimens that were frequently associated 
with marked fat redistribution [49], modern ART regimens 
usually have a more favorable metabolic profile. However, re-
cent studies have identified an association between INSTI-based 
regimens and significant increases in body weight, particu-
larly in women and black individuals [23]. In addition, these 
effects seem to be more pronounced with the use of TAF [23, 
24]. Additional studies are needed to clarify the clinical rele-
vance of this association. Due to the observation period covered 
in our study, we had limited power to detect any influence of 
integrase inhibitor-based regimens or tenofovir alafenamide on 
BMI or WHR changes (dolutegravir and tenofovir alafenamide 
were approved for clinical use in Switzerland in 2015 and 2016, 
respectively).
Ours represents the largest genetic-obesity study undertaken 
in HIV-positive persons. However, Swiss HIV-positive per-
sons with an unfavorable genetic predisposition showed only 
a trend towards a greater BMI increase after 3  years of ART. 
Accounting for CD4 nadir large effect should allow for other 
potentially significant effects to be revealed in the multivariate 
analysis, such as a genetic predisposition effect, if any. This sug-
gests a moderate to small effect of the genetic background on 
BMI and WHR gain, which is accordance with the literature 
from the general population [32, 33, 50]. The power to detect 
any impact of the calculated GRS might have been reduced by 
constraining our genetic analysis to the Caucasians in our study 
population (nBMImodel = 863 and nWHRmodel = 575, Supplementary 
Table 1). Additionally, a modest genetic heterogeneity in our 
study population (median (range) aGRSBMImodel = 86 (67–103); 
wGRSBMImodel = 0.013 (0.010–0.016); aGRSWHRmodel = 46 (35–56); 
wGRSWHRmodel  =  0.013 (0.010–0.017), Supplementary Table 1) 
might have contributed to the lack of significant genetic ef-
fect. A recently published meta-analysis of GWAS for body fat 
distribution in individuals of European ancestry also showed 
that heritability and variant effects were generally stronger in 
women than men [51]. Only 20% of our study population were 
women (Table 1). It also is possible that any genetic effect was 
masked by other more important factors associated with BMI 
and WHR increase. Limitations of our analysis include lack of 
information on diet, alcohol consumption, physical activity, in-
flammatory state of participants, and ultimately a comparison 
with a Swiss HIV-negative cohort.
The present models identified the critical period of 1.5 and 
2.5 years after ART initiation where HIV-infected individuals 
are more prone to increase their BMI and WHR, respectively. 
These findings support the need to inform individuals starting 
ART about the likely early-on body composition changes de-
spite the benefits of starting ART that vastly outweigh this risk. 
Regular monitoring and implementation of early weight man-
agement interventions to address body weight and fat gain are 
to be encouraged, especially in individuals initiating ART with 
a low nadir CD4 cell count [7, 15, 19, 52, 53]. The present BMI 
and WHR models also can be applied to test the efficacy of such 
interventions, either pharmacological or lifestyle modifications, 
at different time points after ART initiation and further devel-
oped into joint models to predict incidence of CV events in the 
HIV-infected population.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
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